# Efficacy and Safety Study of QVA149 in COPD Patients

> **NCT02487446** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 357 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** QVA149
- **DRUG:** Umeclidinium/vilanterol
- **DRUG:** Placebo (umeclidinium/vilanterol)
- **DRUG:** Placebo (QVA149)

## Key facts

- **NCT ID:** NCT02487446
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-28
- **Primary completion:** 2016-09-12
- **Final completion:** 2016-09-12
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02487446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02487446, "Efficacy and Safety Study of QVA149 in COPD Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02487446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*